Cytovance Biologics, Inc., a leading full-service contract manufacturer (CMO) of mammalian and microbial biologics, has announced that is going to extend its manufacturing agreement with Precision Biologics, Inc., a Dallas, Texas-based clinical stage biopharmaceutical company.
Precision Biologics has contracted Cytovance Biologics as its CMO to provide technology transfer and additional cGMP manufacturing services of Ensituximab, otherwise known as NEO-102, which is being developed as a therapeutic drug candidate for pancreatic and colorectal cancers. Precision Biologics is advancing its clinical trials with this leading monoclonal antibody candidate, and now with this agreement is going to support its ongoing Phase 2 clinical trials.
“Cytovance has been a valuable partner in helping us reach another milestone in our program directed towards the treatment of pancreatic and colorectal cancers,” said Dr. Albine Martin, COO of Precision Biologics, Inc. The new partnership with Cytovance is designed to further strengthen the companies’ longstanding and growing relationship.
“Our state-of-the-art facilities and experienced staff are prepared to continue the delivery of clinical materials for Precision Biologics,” said Darren Head, President and Chief Executive Officer of Cytovance Biologics, Inc. “We are proud to be an established partner with Precision Biologics and support them in their expanded clinical trial program.”
Precision Biologics, Inc. is a clinical stage biotechnology corporation founded in 2012 and is focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. The company is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials.
Cytovance Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.